Pfizer Inc. will present compelling clinical data across its extensive oncology portfolio at the European Society for Medical Oncology (ESMO) Congress 2025, taking place October 17-21 in Berlin, Germany. The pharmaceutical giant will showcase data from more than 45 company-sponsored, investigator-sponsored, and collaborative research abstracts, including 11 oral/mini oral presentations and five late-breaking sessions across core scientific modalities and key tumor areas.
"At ESMO, Pfizer is demonstrating how earlier interventions with our innovative medicines have the potential to deliver greater impact to even more patients," said Jeff Legos, Chief Oncology Officer at Pfizer. "The survival benefits we're seeing across certain cancer types reinforce our commitment to accelerating innovative medicines that bring new hope to patients everywhere, while pipeline data highlight the next wave of potential breakthroughs that could transform care for even more people living with cancer."
Presidential Symposium Highlights Unprecedented Bladder Cancer Results
The most significant presentation will occur during a Presidential Symposium, featuring unprecedented survival results from the Phase 3 EV-303 trial (KEYNOTE-905). This study evaluated PADCEV (enfortumab vedotin-ejfv), a Nectin-4 directed antibody-drug conjugate (ADC), in combination with KEYTRUDA (pembrolizumab) in patients with muscle-invasive bladder cancer who are ineligible for or declined cisplatin-based chemotherapy. The results demonstrate the potential to redefine the standard of care for these patients.
Prostate Cancer Treatment Advances
Pfizer will present final overall survival results from the Phase 3 EMBARK trial evaluating XTANDI (enzalutamide) in combination with leuprolide and as monotherapy in non-metastatic hormone-sensitive prostate cancer with high-risk biochemical recurrence. These findings highlight the benefit of XTANDI in this earlier line of treatment, potentially expanding treatment options for patients with prostate cancer.
Lung Cancer Combination Therapy Shows Promise
Updated overall survival data from the Phase 2 PHAROS study will demonstrate the efficacy of BRAFTOVI (encorafenib) plus MEKTOVI (binimetinib) in patients with BRAF V600E-mutant metastatic non-small cell lung cancer (NSCLC). The data reinforces this combination as a potential key treatment option for patients with this specific genetic mutation.
Comprehensive Oncology Portfolio
Pfizer's oncology division focuses on three core mechanisms of action to attack cancer from multiple angles: small molecules, antibody-drug conjugates (ADCs), and multispecific antibodies, including other immune-oncology biologics. The company targets some of the world's most common cancers, including breast cancer, genitourinary cancer, hematology-oncology, and thoracic cancers.
The ESMO presentations represent collaborative efforts with multiple partners. Pfizer and Astellas maintain a clinical collaboration agreement with Merck to evaluate the combination of PADCEV and KEYTRUDA in patients with previously untreated metastatic urothelial cancer. XTANDI is jointly developed and commercialized by Pfizer and Astellas in the United States, while the PHAROS trial is conducted with support from Pierre Fabre.
These clinical developments underscore Pfizer's commitment to advancing cancer care through innovative therapeutic approaches and earlier intervention strategies across multiple tumor types.
